NA Cancer Research Results
NA, NA: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
HH↓,
Gli1↓, EA caused a significant inhibition in phospho-Akt, Gli1, Gli2, Notch1, Notch3, and Hey1.
GLI2↓,
CDK1/2/5/9↓,
p‑Akt↓,
NOTCH1↓,
Shh↓,
Snail↓,
E-cadherin↑,
NOTCH3↓,
HEY1↓,
TumCG↓, EA resulted in significant inhibition in tumor growth which was associated with suppression of cell proliferation and caspase-3 activation, and induction of PARP cleavage.
TumCP↓,
Casp3↑,
cl‑PARP↑,
Bcl-2↓, EA inhibited the expression of Bcl-2, cyclin D1, CDK2, and CDK6, and induced the expression of Bax in tumor tissues compared to untreated control group
cycD1/CCND1↓,
CDK2↓,
CDK6↓,
BAX↑,
COX2/PTGS2↓, EA inhibited the markers of angiogenesis (COX-2, HIF1α, VEGF, VEGFR, IL-6 and IL-8), and metastasis (MMP-2 and MMP-9) in tumor tissues.
Hif1a↓,
VEGF↓,
VEGFR2/KDR/Flk1↓,
IL6↓,
IL8↓,
MMP2↓,
MMP9↓,
NA↓, EA could effectively inhibit human pancreatic cancer growth by suppressing Akt, Shh and Notch pathways
*BioAv↓, IBC has low bioavailability, but can penetrate the blood-brain barrier and is widely distributed in the brain.
*BBB↑,
*hepatoP↓, However, due to its hepatotoxicity, there may be more drug interactions.
ROS↑, Mechanically, IBC can induce the production of reactive oxygen species (ROS), inhibit AKT, ERK, and Wnt pathways, and promote apoptosis of cancer cells through mitochondrial or endoplasmic reticulum pathways.
*NA↓,
ERK↓,
Wnt↓,
Apoptosis↑,
*NF-kB↓, IBC can inhibit the NF-κB pathway and the production of multiple inflammatory mediators by activating NRF2/HO-1 pathway, thus producing anti-inflammatory effects.
*NRF2↑,
*HO-1↑,
*Inflam↓,
Showing Research Papers: 1 to 2 of 2
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned(tgid=0) ⓘ
NA↓, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↑, 1,
Cell Death(tgid=5) ⓘ
p‑Akt↓, 1, Apoptosis↑, 1, BAX↑, 1, Bcl-2↓, 1, Casp3↑, 1, HEY1↓, 1,
DNA Damage & Repair(tgid=10) ⓘ
cl‑PARP↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK1/2/5/9↓, 1, CDK2↓, 1, cycD1/CCND1↓, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
ERK↓, 1, Gli1↓, 1, HH↓, 1, NOTCH1↓, 1, NOTCH3↓, 1, Shh↓, 1, TumCG↓, 1, Wnt↓, 1,
Migration(tgid=13) ⓘ
E-cadherin↑, 1, GLI2↓, 1, MMP2↓, 1, MMP9↓, 1, Snail↓, 1, TumCP↓, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
Hif1a↓, 1, VEGF↓, 1, VEGFR2/KDR/Flk1↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
COX2/PTGS2↓, 1, IL6↓, 1, IL8↓, 1,
Hormonal & Nuclear Receptors(tgid=20) ⓘ
CDK6↓, 1,
Clinical Biomarkers(tgid=22) ⓘ
IL6↓, 1,
Total Targets: 34
Pathway results for Effect on Normal Cells:
NA, unassigned(tgid=0) ⓘ
NA↓, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
HO-1↑, 1, NRF2↑, 1,
Barriers & Transport(tgid=15) ⓘ
BBB↑, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
Inflam↓, 1, NF-kB↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 1,
Functional Outcomes(tgid=23) ⓘ
hepatoP↓, 1,
Total Targets: 8
Scientific Paper Hit Count for: NA, NA
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:0 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page